A phase 2 study of immunogenic cell death inducer PT-112 in patients with metastatic castration-resistant prostate cancer.

被引：0
|
作者：
Bryce, Alan Haruo
Karp, Daniel D.
Tagawa, Scott T.
Nordquist, Luke T.
Rathkopf, Dana E.
Adra, Nabil
Dorff, Tanya B.
Baeck, Johan
O'Donnell, Joseph Francis
Ames, Tyler David
Yim, Christina Y.
Price, Matthew
Scher, Howard I.
机构：
[1] Mayo Clin, Phoenix, AZ USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[3] Cornell Univ, Weill Cornell Med Coll, New York, NY USA
[4] Urol Canc Ctr PC, Omaha, NE USA
[5] Mem Sloan Kettering Canc Ctr, New York, NY USA
[6] Weill Cornell Med, New York, NY USA
[7] Indiana Univ, Simon Comprehens Canc Ctr, Indianapolis, IN USA
[8] City Hope Natl Med Ctr, Duarte, CA USA
[9] Promontory Therapeut Inc, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS292
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Characterization of PSA at death in patients with metastatic castration-resistant prostate cancer.
    Bikkasani, Krishna
    Qin, Qian
    Lin, Justin
    Galsky, Matt D.
    Liaw, Bobby Chi-Hung
    Oh, William K.
    Tsao, Che-Kai
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [2] A phase 1b study of novel immunogenic cell death inducer PT-112 plus PD-L1 inhibitor avelumab in metastatic castrate-resistant prostate cancer (mCRPC) patients.
    Bryce, Alan Haruo
    Dronca, Roxana Stefania
    Costello, Brian Addis
    Aparicio, Ana
    Subudhi, Sumit Kumar
    O'Donnell, Joseph F.
    Jimeno, Jose
    Yim, Christina Yeaeun
    Ames, Tyler David
    Price, Matthew
    Karp, Daniel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] Phase I study of PT-112, a novel pyrophosphate-platinum immunogenic cell death inducer, in advanced solid tumours
    Karp, Daniel D.
    Camidge, D. Ross
    Infante, Jeffery R.
    Ames, Tyler D.
    Price, Matthew R.
    Jimeno, Jose
    Bryce, Alan H.
    ECLINICALMEDICINE, 2022, 49
  • [4] PT-112 induces potent mitochondrial stress and immunogenic cell death in human prostate cancer cell lines
    Soler-Agesta, Ruth
    Ames, Tyler D.
    Price, Matthew
    Jimeno, Jose
    Yim, Christina Y.
    Moreno-Loshuertos, Raquel
    Anel, Alberto
    CANCER RESEARCH, 2022, 82 (12)
  • [5] PT-112, a novel immunogenic cell death inducer, causes ribosomal biogenesis inhibition and organelle stress in cancer cells
    Yim, Christina Y.
    Congenie, Maria T.
    Johnson, Hannah L.
    Mancini, Maureen G.
    Stossi, Fabio
    Mancini, Michael A.
    Azofeifa, Joey
    Price, Matthew R.
    Baeck, Johan
    Ames, Tyler D.
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [6] A phase I study of capivasertib in combination with abiraterone acetate in patients with metastatic castration-resistant prostate cancer.
    Shore, Neal D.
    Mellado, Begona
    Shah, Satish
    Hauke, Ralph J.
    Costin, Dan
    Morris, Thomas
    Anjum, Rana
    Szijgyarto, Zsolt
    Verheijen, Remy B.
    Cullberg, Marie
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [7] Phase II Study with metastatic castration-resistant Prostate Cancer (mCRPC) Patients
    Rexer, H.
    Graefen, M.
    UROLOGE, 2017, 56 (11): : 1468 - 1470
  • [8] Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer
    Yu, Evan Y.
    Wilding, George
    Posadas, Edwin
    Gross, Mitchell
    Culine, Stephane
    Massard, Christophe
    Morris, Michael J.
    Hudes, Gary
    Calabro, Fabio
    Cheng, Shinta
    Trudel, Geralyn C.
    Paliwal, Prashni
    Sternberg, Cora N.
    CLINICAL CANCER RESEARCH, 2009, 15 (23) : 7421 - 7428
  • [9] Cancer cell-selective induction of mitochondrial stress and immunogenic cell death by PT-112 in human prostate cell lines
    Soler-Agesta, R.
    Moreno-Loshuertos, R.
    Yim, C. Y.
    Congenie, M. T.
    Ames, T. D.
    Johnson, H. L.
    Stossi, F.
    Mancini, M. G.
    Mancini, M. A.
    Ripolles-Yuba, C.
    Marco-Brualla, J.
    Junquera, C.
    Martinez-De-Mena, R.
    Enriquez, J. A.
    Price, M. R.
    Jimeno, J.
    Anel, A.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)
  • [10] A phase II study of sEphB4-HSA in metastatic castration-resistant prostate cancer.
    Vander Weele, David James
    Kocherginsky, Masha
    Munir, Sabah
    Martone, Brenda K.
    Morgans, Alicia K.
    Stadler, Walter Michael
    Abdulkadir, Sarki
    Hussain, Maha H. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
12345